Spots Global Cancer Trial Database for pd l2
Every month we try and update this database with for pd l2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | NCT03976362 | Carcinoma, Squa... | Pembrolizumab Carboplatin Paclitaxel Nab-paclitaxel Olaparib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | NCT03976362 | Carcinoma, Squa... | Pembrolizumab Carboplatin Paclitaxel Nab-paclitaxel Olaparib Placebo | 18 Years - | Merck Sharp & Dohme LLC |